Pyridine Carboxamide Nav1.8 Inhibitors With Selective Pain Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain, such as steroidal and nonsteroidal anti-inflammatory drugs, amine reuptake inhibitors, and opioids, have liabilities, and selective inhibitors for voltage-gated sodium channels, particularly Nav1.7 and Nav1.8, have shown limited efficacy in clinical trials, while Nav1.8 inhibitors face challenges with selectivity and pharmacokinetics.
Innovation Solution
Development of pyridine carboxamide compounds that modulate, inhibit, or treat conditions associated with increased Nav1.8 activity or expression, including pain, respiratory diseases, and neurological disorders, by administering a modulating or inhibiting-effective amount of specific compounds of formula (I) to subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective Nav1.7 or Nav1.8 inhibitors are developed, then pain management efficacy is improved, but selectivity and pharmacokinetic properties deteriorate
Solution Approach 1:
The patent applies parameter changes by systematically modifying chemical structures of pyridine carboxamide compounds, specifically adjusting substituents at positions R1, R2, R3, and R4 to optimize the balance between Nav1.8 inhibition potency and selectivity. This involves changing molecular parameters such as substituent types (halogen, alkyl, aryl groups), their positions, and combinations to achieve desired pharmacokinetic profiles while maintaining efficacy.
Solution Approach 2:
The patent implements local quality by introducing specific substituents at particular positions on the pyridine carboxamide core structure. Different substituent patterns (e.g., fluorine at R3, methyl at R4, or specific aryl groups at R1 and R2) create localized molecular characteristics that enhance selectivity for Nav1.8 over other sodium channel isoforms while maintaining appropriate pharmacokinetic properties.
2Adaptability or versatility
If non-selective sodium channel inhibitors are used, then broad pain coverage is achieved, but adverse effects increase
Solution Approach 1:
The patent achieves selective inhibition of Nav1.8 through localized molecular modifications on the pyridine carboxamide scaffold. By placing specific substituents at defined positions (R1-R4), the compounds exhibit preferential binding to Nav1.8 channels while sparing other sodium channel isoforms, thereby providing targeted pain relief with reduced adverse effects compared to non-selective inhibitors.
Solution Approach 2:
The pyridine carboxamide compounds act as selective intermediaries that specifically target Nav1.8 channels expressed in nociceptive neurons. This selective intermediary action allows the patent to achieve pain management efficacy while avoiding the broad-spectrum adverse effects associated with non-selective sodium channel inhibitors, as the compounds do not significantly bind to Nav1.1, Nav1.2, Nav1.3, or other isoforms.
Data Source
AI summary
Pyridine carboxamide compounds for inhibiting Nav1.8 and methods for treating a condition, disease, or disorder associated with an increased Nav1.8 activity or expression are disclosed.